Revolution Medicines Inc (RVMD NASDAQ) stock market data APIs
$206.2857
-5.59(-2.7%)
as of August 7, 2026
Try our APIs with
free plan!
Revolution Medicines Inc Financial Data Overview
Price chart is built with
Anychart
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
206.2857
Open
200.6955
High
206.466
Low
195.1862
52 wk Range
34.14-205.9
Market Cap
43 971 M
Shares Outstanding
214 M
Revenue
742 K
EPS
-2.34
Beta
1.403
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Revolution Medicines Inc (top by weight)
Ticker
100-day Price Change
Weight
W311.XETRA
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
0.95
(15.11%)
4.43
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revolution Medicines Inc data using free add-ons & libraries
Get Revolution Medicines Inc Fundamental Data
Revolution Medicines Inc Fundamental data includes:
- Net Revenue: 742 K
- EBITDA: -1 378 393 984
- Earnings Per Share: -9
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Revolution Medicines Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -1.93
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revolution Medicines Inc News
New
Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target
(RTTNews) - Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company, reported second-quarter financial results reflecting a wider net loss. In addition, the company provided an updat...
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines RVMD reported an adjusted loss of $2.34 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.93. The adjusted figure excluded a non-ca...
Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ...
This article first appeared on GuruFocus. Cash and Investments: $3.9 billion at the end of Q2 2026, including $2.2 billion in gross proceeds from public offerings and a $250 million royalty tranche f...
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results Rapi...
Get Revolution Medicines Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
